Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects.

ABSTRACT:

Aims

The aim of the present study was to characterize the pharmacokinetics and exposure-subjective response relationship of a novel oral solution of lysergic acid diethylamide (LSD) that was developed for clinical use in research and patients.

Method

LSD (100 μg) was administered in 27 healthy subjects using a placebo-controlled, double-blind, cross-over design. Plasma levels of LSD, nor-LSD, and 2-oxo-3-hydroxy-LSD (O-H-LSD) and subjective drug effects were assessed up to 11.5 hours.

Results

First-order elimination kinetics were observed for LSD. Geometric mean maximum concentration (C_max ) values (range) of 1.7 (1.0-2.9) ng/mL were reached at a t_max (range) of 1.7 (1.0-3.4) hours after drug administration. The plasma half-life (t_1/2

SUBMITTER: Holze F 

PROVIDER: S-EPMC6595343 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature